comparemela.com

Latest Breaking News On - Aptevo therapeutics daily - Page 1 : comparemela.com

Roth Capital Research Analysts Cut Earnings Estimates for Aptevo Therapeutics Inc (NASDAQ:APVO)

Roth Capital Research Analysts Cut Earnings Estimates for Aptevo Therapeutics Inc (NASDAQ:APVO)
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

Q2 2024 EPS Estimates for Aptevo Therapeutics Inc Cut by Roth Capital (NASDAQ:APVO)

Q2 2024 EPS Estimates for Aptevo Therapeutics Inc Cut by Roth Capital (NASDAQ:APVO)
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Aptevo Therapeutics Inc (NASDAQ:APVO) Short Interest Update

Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Free Report) saw a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 28,900 shares, a growth of 725.7% from the February 29th total of 3,500 shares. Based on an average trading volume of 91,700 shares, the days-to-cover ratio […]

StockNews com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO)

StockNews com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews com

StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO – Get Free Report) in a report released on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock. Aptevo Therapeutics Stock Performance Shares of APVO opened at $0.14 on Thursday. The firm’s fifty day simple moving average is $0.16 and its 200-day simple […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.